The Immunoassay of Human UrokinaseSupported by Contract AT-(40-1)-3195 with the U.S. Atomic Energy Commission and Grant No. HE-08929 with the National Institutes of Health, USPHS.
10 June 2018 (online)
Urokinase with an activity of 45,200 CTA nnits/mg was used in 0.4 mg amounts with Freund’s adjuvant to immunize four individual rabbits by two injections spaced 4 weeks apart. All antisera were titrated for inhibition of urokinase activation of plasminogen, for double diffusion in Agarose, and for immunoelectrophoresis. Against constant portions of 125I-labelled IgG from each antiserum, 131I-labelled urokinase was titrated by the quantitative precipitin technique. The results from these 4 methods of titration were compared and out of them the following conclusions were drawn :
1. There were 3 main immunogens in the urokinase preparations, one inactive as an activator, one with questionable activity, and one definitely and strongly active as a urokinase. The first two comprised less than 5% of the total antigen mixture; the active third component was more than 20% of the total. About 75% of the total protein was non-precipitable with antibody and was inactive as an activator. One inactive immunogen, I, was a fast β-protein in immunoelectrophoresis at pH 8.2, ionic strength 0.05: the questionably active immunogen, II, was a γ-protein; the active third component, III, was a slow β-protein whose specific activity was estimated to be 230,000 CTA units/mg protein.
2. Antibodies against I and II were in considerably higher titer than the ones to III and their equivalence points were reached at much higher concentrations of added urokinase preparation. A single precipitin line instead of 3 could be obtained by the use of very dilute antisera, but the line was due to the inactive I, not the slow active β-protein, III, nor the questionably active γ-protein, II.
3. All 4 antisera were 100% inhibitory of plasminogen activation activity at the equivalence point of III, but were not inhibitory at the equivalence points of I and II.
4. Urokinase when added to normal human serum could be visualized as easily in double diffusion as when tested in buffer alone.
- 1 Kucinshi G, Fletcher A. Immunologic distinction between human plasma plasminogen activator and human urokinase (abstract). Fed. Proc 25: 194 1966;
- 2 Kucinshi G, Fletcher A, Sherry S. Effect of Urokinase antiserum on plasminogen activators : Demonstration of immunologic dissimilarity between plasma plasminogen activator and urokinase. J. clin. Invest 47: 1238 1968;
- 3 Bernik M, Kwaan HG. Origin of fibrinolytic activity in cultures of human kidney. J. Lab. clin. Invest 70: 650 1967;
- 4 Day ED, Planinsek J, Korngold L, Pressman D. Tumor-localizing antibodies purified from antisera against Murphy rat lymphosarcoma. J. nat. Cancer Inst 17: 517 1956;
- 5 Day ED, Lassiter S, Fritz RB. Radioiodination of antibodies adsorbed to insoluble antigens. J. Immunol 98: 67 1967;
- 6 Fritz RB, Lassiter S, Day ED. A quantitative precipitin study of porcine fibrinogen employing paired labels. J. Immunol 98: 1213 1967;
- 7 Johnson A, Day ED, Pressman D. The effect of iodination on antibody activity. J. Immunol 84: 213 1960;
- 8 Fritz RB, Lassiter S, Day ED. The effect of iodination on antifibrinogen antibodies with respect to precipitating and adsorption activities. Immunochem 04: 283 1967;
- 9 Pollock MR. Stimulating and inhibiting antibodies for bacterial penicillinase. Immunol 07: 707 1964;
- 10 White WF, Barlow GH, Mozen MM. The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 05: 2160 1966;